480 related articles for article (PubMed ID: 17576940)
21. Role of azathioprine in preventing recurrences in a patient of recurrent erythema nodosum leprosum.
Verma KK; Srivastava P; Minz A; Verma K
Lepr Rev; 2006 Sep; 77(3):225-9. PubMed ID: 17172003
[TBL] [Abstract][Full Text] [Related]
22. NUDT15 polymorphism identified in a patient with azathioprine hypersensitivity syndrome presenting as erythema nodosum and hepatotoxicity.
Wang CH; Chi MH; Lin JY; Chung WH; Chen CB
Br J Dermatol; 2019 Sep; 181(3):631-632. PubMed ID: 30843183
[No Abstract] [Full Text] [Related]
23. Three hospital admissions in 9 days to diagnose azathioprine hypersensitivity in a patient with Crohn's disease.
Mookherjee S; Narayanan M; Uchiyama T; Wentworth KL
Am J Ther; 2015; 22(2):e28-32. PubMed ID: 23782763
[TBL] [Abstract][Full Text] [Related]
24. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
Cao Q; Zhu Q; Shang Y; Gao M; Si J
Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
[TBL] [Abstract][Full Text] [Related]
25. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
[TBL] [Abstract][Full Text] [Related]
26. Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.
Shah JA; Edwards CM; Probert CS
Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):169-73. PubMed ID: 18301295
[TBL] [Abstract][Full Text] [Related]
27. Erythema nodosum in renal transplant recipients: multiple cases and review of literature.
Gheith O; Al-Otaibi T; Tawab KA; Said T; Balaha MA; Halim MA; Nair MP; Nampoory MR
Transpl Infect Dis; 2010 Apr; 12(2):164-8. PubMed ID: 20002354
[TBL] [Abstract][Full Text] [Related]
28. Natural history of azathioprine-associated lymphopenia in inflammatory bowel disease patients: a prospective observational study.
Al Rifai A; Prasad N; Shuttleworth E; McBurney H; Pushpakom S; Robinson A; Newman W; Campbell S
Eur J Gastroenterol Hepatol; 2011 Feb; 23(2):153-8. PubMed ID: 21164349
[TBL] [Abstract][Full Text] [Related]
29. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
[TBL] [Abstract][Full Text] [Related]
30. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression.
Peyrin-Biroulet L; Cadranel JF; Nousbaum JB; Oussalah A; Seddik M; Canva V; Cortot A; Sogni P; Gueant JL; Bigard MA; Roblin X; Bronowicki JP
Aliment Pharmacol Ther; 2008 Oct; 28(8):984-93. PubMed ID: 18657132
[TBL] [Abstract][Full Text] [Related]
31. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
[TBL] [Abstract][Full Text] [Related]
32. Azathioprine hypersensitivity mimicking an acute exacerbation of dermatomyositis.
Goldenberg DL; Stor RA
J Rheumatol; 1975 Sep; 2(3):346-9. PubMed ID: 1185746
[TBL] [Abstract][Full Text] [Related]
33. Potassium iodide in the treatment of erythema nodosum and nodular vasculitis.
Horio T; Imamura S; Danno K; Ofuji S
Arch Dermatol; 1981 Jan; 117(1):29-31. PubMed ID: 7458376
[TBL] [Abstract][Full Text] [Related]
34. The cutaneous and systemic manifestations of azathioprine hypersensitivity syndrome.
Bidinger JJ; Sky K; Battafarano DF; Henning JS
J Am Acad Dermatol; 2011 Jul; 65(1):184-91. PubMed ID: 21496951
[TBL] [Abstract][Full Text] [Related]
35. Development of Beau's lines in two patients receiving azathioprine.
Makhzoumi Z; DeCapite T; Gaspari A
J Dermatolog Treat; 2009; 20(4):246-7. PubMed ID: 19255920
[TBL] [Abstract][Full Text] [Related]
36. Patients with inflammatory bowel disease: their response to information leaflets about medical therapy in particular azathioprine.
Ward B; Shah S; Eaden JA; Mayberry JF
Arq Gastroenterol; 1998; 35(4):264-6. PubMed ID: 10347709
[TBL] [Abstract][Full Text] [Related]
37. Azathioprine Therapy in a Pediatric TPMT-Deficient Patient-Still an Option.
van Moorsel SA; Bevers N; Meurs M; van Rossum LK; Hooymans PM; Wong DR
Ther Drug Monit; 2017 Feb; 39(1):1-4. PubMed ID: 28081040
[TBL] [Abstract][Full Text] [Related]
38. Azathioprine hypersensitivity-like reactions--a case report and a review of the literature.
Knowles SR; Gupta AK; Shear NH; Sauder D
Clin Exp Dermatol; 1995 Jul; 20(4):353-6. PubMed ID: 8549000
[TBL] [Abstract][Full Text] [Related]
39. Erythema nodosum: a sign of systemic disease.
Schwartz RA; Nervi SJ
Am Fam Physician; 2007 Mar; 75(5):695-700. PubMed ID: 17375516
[TBL] [Abstract][Full Text] [Related]
40. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease.
Ananthakrishnan AN; Attila T; Otterson MF; Lipchik RJ; Massey BT; Komorowski RA; Binion DG
J Clin Gastroenterol; 2007 Aug; 41(7):682-8. PubMed ID: 17667053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
